Rilotumumab (AMG 102)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Rilotumumab (AMG 102), covering 2016-02-29 to 2016-02-29. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ [Phase 1]